Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Leveraging Generative AI to Prioritize Drug Repurposing Candidates: Validating Identified Candidates for Alzheimer's Disease in Real-World Clinical Datasets.

medRxiv : the preprint server for health sciences·2023
Same author

Cardiac Sarcoidosis and a Likely Pathogenic <i>TTN</i> Variant in a Patient Presenting With Ventricular Tachycardia.

JACC. Case reports·2023
Same author

High-throughput functional mapping of variants in an arrhythmia gene, <i>KCNE1</i>, reveals novel biology.

bioRxiv : the preprint server for biology·2023
Same author

Detection of distant familial relatedness in biobanks for identification of undiagnosed carriers of a Mendelian disease variant: application to Long QT syndrome.

medRxiv : the preprint server for health sciences·2023
Same author

Multicenter clinical and functional evidence reclassifies a recurrent noncanonical filamin C splice-altering variant.

Heart rhythm·2023
Same author

Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results.

Circulation. Genomic and precision medicine·2023

相关实验视频

Updated: Jul 7, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

IKs通道复合体的酸化抑制药物阻断:一种新的机制,是变量抗不律性药物作用的基础.

Tao Yang1, Hideaki Kanki, Dan M Roden

  • 1Division of Clinical Pharmacology, Vanderbilt University School of Medicine, RRB532C, Nashville, TN 37232, USA.

Circulation
|July 2, 2003
PubMed
概括
此摘要是机器生成的。

蛋白激酶A (PKA) 刺激降低了抗心律失常药物对心脏的阻断作用.

更多相关视频

Controllable Ion Channel Expression through Inducible Transient Transfection
10:00

Controllable Ion Channel Expression through Inducible Transient Transfection

Published on: February 17, 2017

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

相关实验视频

Last Updated: Jul 7, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Controllable Ion Channel Expression through Inducible Transient Transfection
10:00

Controllable Ion Channel Expression through Inducible Transient Transfection

Published on: February 17, 2017

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

科学领域:

  • 心脏病学 心脏病学
  • 分子生物学分子生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • IKs电流对于心脏再极化至关重要,是抗心律失常药物的目标.
  • 蛋白激酶A (PKA) 的激活显著增加了IKs的电流,通常由β-上腺刺激触发.
  • β-上腺刺激可以导致心律失常,这表明PKA在药物作用中的潜在保护作用.

研究的目的:

  • 调查PKA刺激抑制抗心律不良药对IKs通道的阻断作用的假设.
  • 阐明PKA调节药物通道相互作用的机制.

主要方法:

  • 中国仓鼠卵巢 (CHO) 细胞被KCNQ1cDNA感染,有或没有KCNE1亚单元.
  • 对基底和PKA刺激的IK测量了素和克罗曼醇293B的药物敏感性 (IC50).
  • 用局部定向的突变发生法来创建抗PKA的IKs通道突变.

主要成果:

  • 通过PKA刺激,素阻断剂的IC50增加了3倍以上,这表明药物敏感性降低.
  • 与基底道相比,PKA刺激的IKs道显示药物阻断的发展明显较慢.
  • 一种KCNQ1的PKA耐药突变保留了野生类型的药物敏感性,不受PKA刺激的影响.

结论:

  • 激活PKA显著降低了抗失常药物阻断IKs通道的情况.
  • 通过PKA对KCNQ1亚单元的酸化直接影响药物与道的结合.
  • 这种PKA介导的药物通道相互作用调节机制在β-上腺素刺激期间可能特别重要,以预防心律失常.